A traditional Chinese medicine moxa stick for treating allergic rhinitis of lung and spleen qi deficiency type by tonifying lung and regulating spleen

Abstract

This invention relates to a traditional Chinese medicine moxa stick for treating allergic rhinitis caused by lung and spleen qi deficiency. It possesses the functions of warming the meridians, dispelling cold, and regulating the internal organs, thus addressing the medication issues associated with this condition. The stick is made from traditional Chinese medicine and moxa wool. The medicine consists of raw astragalus, atractylodes macrocephala, codonopsis pilosula, angelica dahurica, saposhnikovia divaricata, tangerine peel, magnolia flower bud, mint, and dried ginger, all ground into a fine powder and dried. This powder is then mixed evenly with moxa wool to form the medicine. Mulberry bark paper is rolled into a tube, coated evenly with egg white, wrapped with another layer of mulberry bark paper, dried, and then the tube is filled with the medicine and compacted to create the finished moxa stick. This invention features a scientifically sound formula, a simple and easy-to-operate preparation method, and convenient use. It allows the medicine and the heat of the moxa to work synergistically, directly reaching the meridians to warm the meridians, dispel cold, and regulate the internal organs. Simultaneously, it achieves multiple effects, including tonifying lung qi, invigorating spleen yang, and resolving dampness and stagnation. By enhancing lung and spleen function, it strengthens the body's disease resistance and repair capabilities, effectively treating allergic rhinitis caused by lung and spleen qi deficiency, and has practical clinical and promotional application value.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine, and in particular to a moxa stick for treating allergic rhinitis of the lung and spleen deficiency type by tonifying the lung and strengthening the spleen. Background Technology

[0002] With the accelerated pace of modern life, increased work pressure, and long-term irregular lifestyles, unhealthy habits are becoming increasingly common, and the incidence of lung and spleen qi deficiency syndrome has risen significantly, becoming a common problem affecting the quality of life of modern people. Modern people spend long hours working at desks, sitting for long periods with little movement, and excessive thinking, which depletes spleen qi; irregular diets, or excessive consumption of raw, cold, and greasy foods, damage spleen yang, further hindering spleen function; excessive reliance on air conditioning in summer and the consumption of cold drinks allow cold air to directly attack the spleen and stomach, also suppressing lung and defensive qi; disordered lifestyles, with staying up late becoming the norm, not only deplete yin and blood but also prevent yang qi from being stored properly, weakening the body's defensive qi.

[0003] The lungs govern qi and respiration, and are externally connected to the skin and hair. When lung qi is deficient, the body's defensive qi is weak, resulting in symptoms such as shortness of breath, weak voice, weak cough and wheezing, aversion to wind and spontaneous sweating, recurrent colds, nasal congestion with clear runny nose, pale tongue with white coating, and weak pulse. The spleen governs transportation and transformation, and is the source of qi and blood production. When spleen qi is deficient, transportation and transformation are impaired, resulting in symptoms such as loss of appetite, abdominal distension after meals, loose stools, fatigue, sallow complexion, pale and swollen tongue with teeth marks, and slow and weak pulse. When both the lungs and spleen are deficient in qi, the transformation of food essence into nutrients is insufficient, clear qi cannot be transported upwards, the generation of ancestral qi is lacking, and the body's disease resistance and repair capabilities decline across the board.

[0004] The patient suffers from lung and spleen qi deficiency, resulting in weakened body defenses and susceptibility to external pathogens. Dysfunction of the digestive system leads to the internal generation of dampness and phlegm, ultimately presenting a syndrome characterized by persistent weakness and dysfunction. This results in recurrent respiratory infections, often manifesting as nasal itching, continuous sneezing, copious clear nasal discharge, nasal congestion, and cough, which is allergic rhinitis (AR). Although this condition is not as acute as acute pain, it can have a long-term and continuous impact on the patient's quality of life and health.

[0005] Moxibustion is an important means of treating diseases. It utilizes the heat generated by burning mugwort leaves to act on acupoints and meridians on the body surface, providing a warm stimulus to the body, thereby warming the meridians, dispelling cold, and regulating the internal organs to achieve the purpose of treating diseases. However, the quality of moxa sticks on the market varies greatly, and the ingredients are often singular, lacking precise formulations targeting the specific and complex pathogenesis of "lung and spleen qi deficiency." Moreover, relying solely on the warming properties of moxa wool makes it difficult to simultaneously achieve the multiple effects of tonifying lung qi, invigorating spleen yang, and resolving dampness and stagnation, failing to reflect the core advantages of traditional Chinese medicine's "syndrome differentiation and treatment, and precise medication." This application proposes to create a lung-tonifying and spleen-strengthening moxa stick by mixing a formula of medicinal ingredients with moxa wool, specifically targeting allergic rhinitis caused by lung and spleen qi deficiency. This medicinal moxa stick aims to achieve a synergistic effect of the medicine and the heat of moxa through acupoint moxibustion, directly reaching the meridians to more effectively improve related symptoms, enhance the patient's constitution, and improve their overall health and quality of life. However, no public reports have been found to date on this topic. Summary of the Invention

[0006] In view of the above situation and to overcome the shortcomings of the existing technology, the purpose of this invention is to provide a traditional Chinese medicine moxa stick for treating allergic rhinitis of the lung and spleen deficiency type, which has the effects of warming the meridians and dispelling cold, regulating and tonifying the internal organs, and can effectively improve symptoms such as pale complexion, fatigue, shortness of breath, weakness in the limbs, poor appetite and loose stools caused by lung and spleen deficiency, thus solving the problem of medication for treating allergic rhinitis of the lung and spleen deficiency type.

[0007] The technical solution provided by this invention is: a traditional Chinese medicine moxa stick for treating allergic rhinitis of the lung and spleen deficiency type, which is made from Chinese herbs and moxa wool by weight. The Chinese herbs are: 9-11g of raw Astragalus membranaceus, 5.5-6.5g of Atractylodes macrocephala, 2.5-3.5g of Codonopsis pilosula, 2.5-3.5g of Angelica dahurica, 2.5-3.5g of Saposhnikovia divaricata, 2.5-3.5g of Citrus reticulata peel, 2.5-3.5g of Magnolia biondii, 2.5-3.5g of Mentha haplocalyx, and 1.8-2.2g of dried ginger, which are ground into a fine powder, dried, and then mixed with 2.5 times the weight of moxa wool to form the medicine. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 1.6-4.0cm, and 5-7 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. Then the medicine is filled into the paper tube and compacted to form the finished traditional Chinese medicine moxa stick.

[0008] This invention uses traditional Chinese medicine in a formula based on the principal, assistant, adjuvant, and guide relationships, which is scientific and reasonable. The preparation method is simple, easy to operate, and convenient to use. It allows the medicine to work synergistically with the heat of moxibustion, directly reaching the meridians, warming the meridians and dispelling cold, regulating and tonifying the internal organs. At the same time, it achieves multiple effects such as tonifying lung qi, invigorating spleen yang, and resolving dampness and stagnation. By improving lung and spleen function, it enhances the body's disease resistance and repair ability from the root, reverses the state of chronic deficiency, and effectively treats allergic rhinitis of the lung and spleen qi deficiency type. It has practical clinical and promotional application value. Detailed Implementation

[0009] The specific implementation of the present invention will be described in detail below with reference to examples and specific circumstances.

[0010] The present invention can be described in the following embodiments: Example

[0011] This invention relates to a traditional Chinese medicine moxa stick for treating allergic rhinitis of the lung and spleen deficiency type, which is made from Chinese herbs and moxa wool by weight. The Chinese herbs are 10g of raw astragalus, 6g of atractylodes macrocephala, 3g of codonopsis pilosula, 3g of angelica dahurica, 3g of saposhnikovia divaricata, 3g of tangerine peel, 3g of magnolia flower, 3g of mint, and 2g of dried ginger, which are ground into a fine powder, dried, and then mixed with 90g of moxa wool to form the medicine. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 1.6cm, and 5 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. Then the medicine is filled into the paper tube and compacted to form the finished Chinese medicine moxa stick. Example

[0012] This invention relates to a traditional Chinese medicine moxa stick for treating allergic rhinitis of the lung and spleen deficiency type, which is made from Chinese herbs and moxa wool by weight. The Chinese herbs are: 9g of raw Astragalus membranaceus, 5.5g of Atractylodes macrocephala, 2.5g of Codonopsis pilosula, 2.5g of Angelica dahurica, 2.5g of Saposhnikovia divaricata, 2.5g of Citrus reticulata peel, 2.5g of Magnolia biondii, 2.5g of Mentha haplocalyx, and 1.8g of dried ginger, ground into a fine powder, dried, and mixed with 75.75g of moxa wool. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 1.8cm, and 5 layers. Egg white is evenly coated on the surface of the paper tube, then another layer of mulberry bark paper is wrapped around it and dried. The paper tube is then filled with the medicine and compacted to obtain the finished traditional Chinese medicine moxa stick. Example

[0013] This invention relates to a traditional Chinese medicine moxa stick for treating allergic rhinitis of the lung and spleen deficiency type, which is made from Chinese herbs and moxa wool by weight. The Chinese herbs are: 11g of raw Astragalus membranaceus, 6.5g of Atractylodes macrocephala, 3.5g of Codonopsis pilosula, 3.5g of Angelica dahurica, 3.5g of Saposhnikovia divaricata, 3.5g of Citrus reticulata peel, 3.5g of Magnolia biondii, 3.5g of Mentha haplocalyx, and 2.2g of dried ginger, which are ground into a fine powder, dried, and then mixed with 101.75g ​​of moxa wool. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 2.6cm, and 6 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. The paper tube is then filled with the medicine and compacted to obtain the finished Chinese medicine moxa stick. Example

[0014] This invention relates to a traditional Chinese medicine moxa stick for treating allergic rhinitis of the lung and spleen deficiency type, which is made from Chinese herbs and moxa wool by weight. The Chinese herbs are: 9g of raw Astragalus membranaceus, 6.5g of Atractylodes macrocephala, 2.5g of Codonopsis pilosula, 3.5g of Angelica dahurica, 2.5g of Saposhnikovia divaricata, 3.5g of Citrus reticulata peel, 2.5g of Magnolia biondii, 3.5g of Mentha haplocalyx, and 1.8g of dried ginger, ground into a fine powder, dried, and mixed with 88.25g of moxa wool. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 2.8cm, and 6 layers. Egg white is evenly coated on the surface of the paper tube, then another layer of mulberry bark paper is wrapped around it and dried. The paper tube is then filled with the medicine and compacted to obtain the finished traditional Chinese medicine moxa stick. Example

[0015] This invention relates to a traditional Chinese medicine moxa stick for treating allergic rhinitis of the lung and spleen deficiency type, which is made from Chinese herbs and moxa wool by weight. The Chinese herbs are: 11g of raw Astragalus membranaceus, 5.5g of Atractylodes macrocephala, 3.5g of Codonopsis pilosula, 2.5g of Angelica dahurica, 3.5g of Saposhnikovia divaricata, 2.5g of Citrus reticulata peel, 3.5g of Magnolia biondii, 2.5g of Mentha haplocalyx, and 2.2g of dried ginger, which are ground into a fine powder, dried, and then mixed with 91.75g ​​of moxa wool. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 4cm, and 7 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. The paper tube is then filled with the medicine and compacted to obtain the finished traditional Chinese medicine moxa stick.

[0016] The composition given in the above embodiments can be used to prepare any amount of traditional Chinese medicine as needed. The given embodiments are only for illustrating specific implementation methods of the present invention and are not intended to limit the scope of protection of the present invention. The traditional Chinese medicine composition can be made into a series of products of different specifications according to actual needs.

[0017] In the drug combinations given above, among which: Raw Astragalus: Sweet, warm. Enters the Lung and Spleen meridians. Tonifies Qi and strengthens the exterior, tonifies the Spleen and strengthens the Lung.

[0018] Atractylodes macrocephala: Bitter, sweet, and warm. It enters the spleen and stomach meridians. It strengthens the spleen and replenishes qi, dries dampness and promotes diuresis, stops sweating, and calms the fetus.

[0019] Codonopsis pilosula: Sweet, neutral. Enters the spleen and lung meridians. Tonifies the middle energizer and replenishes qi, strengthens the spleen and benefits the lungs.

[0020] Angelica dahurica: pungent in taste, warm in nature, and enters the stomach, large intestine, and lung meridians. It dispels wind and dampness, clears nasal passages, reduces swelling, and drains pus.

[0021] Fangfeng (Saposhnikovia divaricata): Pungent, sweet, and slightly warm in nature. It enters the bladder, lung, spleen, and liver meridians. Its functions include dispelling wind and releasing the exterior, eliminating dampness and relieving pain, relieving spasms, and stopping itching.

[0022] Dried tangerine peel: pungent, bitter, and warm. It enters the spleen and lung meridians. It regulates qi, strengthens the spleen, dries dampness, and resolves phlegm.

[0023] Magnolia flower bud: pungent, warm. It dispels wind-cold and clears nasal passages.

[0024] Peppermint: It has a pungent taste and cool properties, and enters the lung and liver meridians. It disperses wind-heat and clears the head and eyes.

[0025] Dried ginger: pungent and hot. It enters the spleen, stomach, heart, and lung meridians. It warms the middle jiao (spleen and stomach) and dispels cold, warms the lungs and resolves phlegm.

[0026] Mugwort: pungent, bitter, and warm; slightly toxic. It enters the liver, spleen, and kidney meridians. It dispels cold, clears stagnation, and opens the nasal passages.

[0027] Based on the principles of Traditional Chinese Medicine, the above-mentioned components adhere to the "principal, assistant, adjuvant, and guide" formula. Astragalus membranaceus, Codonopsis pilosula, and Atractylodes macrocephala are the principal herbs, all of which enter the lung and spleen meridians, working together to tonify qi, strengthen the exterior, and aid digestion. The aim is to support the body's fundamental balance, replenish lung and spleen qi, and enhance defensive and digestive functions. Dried ginger and tangerine peel are the assistant herbs, warming the middle jiao, dispelling cold, regulating qi, and resolving dampness, assisting the principal herbs in warming and regulating the middle jiao, harmonizing qi, and resolving the mechanism of cold and dampness caused by deficiency. Saposhnikovia divaricata, Angelica dahurica, Magnolia biondii, and Mentha haplocalyx are added as adjuvants, utilizing their aromatic and penetrating properties to dispel wind and cold, specifically designed for lung deficiency and weak defensive qi, and nasal congestion, clearing nasal passages and stopping runny nose, while also invigorating the spleen. Furthermore, moxa wool serves as a carrier, using the warmth of moxibustion to carry the properties of the herbs to the acupoints, leveraging the inherent warming and meridian-clearing, yang-tonifying, and cold-dispelling properties of moxibustion itself, allowing the medicinal effects and heat of moxibustion to complement each other, achieving the therapeutic goal of supporting the body's fundamental balance and eliminating pathogenic factors.

[0028] This formula integrates the functions of replenishing Qi, warming the middle Jiao, dispelling wind, and clearing the orifices, treating both the symptoms and the root cause. Its effects directly target the "Qi deficiency" and "Yang deficiency" inherent in modern society, often caused by overwork, excessive thinking, exposure to cold, and improper diet. By enhancing lung and spleen function, it strengthens the body's resistance and repair capabilities at the fundamental level of "Qi" and "Yang," effectively improving core symptoms such as shortness of breath, fatigue, loss of appetite, aversion to wind, spontaneous sweating, and recurrent nasal symptoms. It offers comprehensive advantages in treating allergic rhinitis caused by lung and spleen Qi deficiency, addressing both the cause and symptoms. It is highly effective, efficient, has no toxic side effects, a short treatment cycle, and no recurrence. Experiments have demonstrated very good and beneficial technical results, as shown in the following experimental materials (using Example 1 as an example): 1. Source of the case:

[0029] This study included 72 patients with lung-spleen qi deficiency type allergic rhinitis who visited the Acupuncture and Otolaryngology Departments of the Third Affiliated Hospital of Henan University of Traditional Chinese Medicine between December 2024 and December 2025. Eligible patients were fully informed of the risks and benefits of this study, signed informed consent forms, and were then randomly assigned to the experimental group and the control group. 2. Diagnostic criteria:

[0030] 2.1 Western medical diagnostic criteria: Refer to the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition).

[0031] (1) Symptoms: Two or more symptoms such as paroxysmal sneezing, clear nasal discharge, nasal itching and nasal congestion occur, and the symptoms last or accumulate for more than 1 hour per day. They may be accompanied by eye symptoms such as tearing, itchy eyes and red eyes. (2) Physical signs: common signs include pale and edematous nasal mucosa and watery nasal discharge; (3) Allergen detection: Positive for at least one allergen SPT and / or serum-specific IgE, or positive for nasal provocation test. 2.2 Diagnostic criteria in Traditional Chinese Medicine:

[0032] Refer to the diagnostic criteria for nasal congestion (lung and spleen qi deficiency syndrome) in "Integrated Traditional Chinese and Western Medicine Otorhinolaryngology"; (1) Main symptoms: ① Nasal itching and discomfort; ② Frequent sneezing; ③ Clear nasal discharge; ④ Nasal congestion; (2) Secondary symptoms: ① Pale complexion; ② Fatigue and shortness of breath; ③ Weakness in the limbs; ④ Poor appetite and loose stools; (3) Tongue and pulse: The tongue is pale and swollen or has teeth marks, the coating is white, and the pulse is soft and slow; The patient has ≥2 of the above primary symptoms; ≥1 of the secondary symptoms ① and ② or ≥1 of the secondary symptoms ③ and ④, with tongue and pulse examination as references, and is diagnosed as having lung and spleen qi deficiency type rhinitis by two attending TCM physicians or senior physicians specializing in this field. 3. Case selection: 3.1 Inclusion criteria:

[0033] (1) Meets the diagnostic criteria of both traditional Chinese medicine and Western medicine; (2) Has not received any related drug treatment in the past month and has no allergy to the drugs used in this treatment; (3) No obvious symptoms of acute respiratory infection were observed upon enrollment; (4) Informed and voluntary researchers; (5) Age between 18 and 65 years old, gender not limited. 3.2 Exclusion Criteria:

[0034] (1) Those suffering from other allergic diseases; (2) For treating local skin ulcers where moxibustion is not suitable; (3) Those who have a history of nasal surgery, or suffer from sinusitis, nasal polyps or other types of rhinitis; (4) Those with severe liver and kidney damage, cardiovascular and cerebrovascular diseases, malignant tumors, autoimmune diseases, or mental abnormalities; (5) Those who are unable to cooperate in completing the trial or are currently participating in other clinical research; (6) Any other circumstances that make a candidate unsuitable for selection during the trial. 3.3 Criteria for Termination:

[0035] (1) A serious adverse event occurred during the experiment; (2) Those who experience adverse reactions during the trial and cannot tolerate the treatment; (3) Those whose condition suddenly worsens during the trial and requires other treatments; (4) Significant deviations occurred in the design or implementation of the experiment, making it difficult to evaluate the drug effect. 3.4 Elimination Criteria:

[0036] (1) Other treatment methods that may affect the efficacy were used during the treatment process; (2) Those with poor compliance, who do not receive treatment as prescribed, and whose treatment effectiveness cannot be determined; (3) Those with incomplete observation data. 3.5. Shedding Criteria:

[0037] (1) Those who voluntarily withdraw from this trial due to a change in personal will and unwillingness to continue participating in clinical observation; (2) Patients who have no follow-up records after treatment are automatically lost to follow-up. 3.6. Handling of lost cases:

[0038] (1) If a subject goes missing, the researcher should try to contact the subject by phone, letter or other means, ask for the reason for the missing subject, and complete the assessment items that can be completed as much as possible. (2) If a participant withdraws from the trial due to allergic reaction, ineffective treatment, or adverse reaction, the researcher should take appropriate measures based on the participant's actual condition. (3) For dropout cases, the researcher must fill in the reasons for dropout in detail in the case report form. Statistical analysis should be combined with actual treatment. If adverse reactions occur, they should be included in the adverse reaction statistics; if more than 1 / 2 of the treatment course is completed, the efficacy should be statistically analyzed. 4. Case grouping:

[0039] This clinical study employed a randomized controlled trial, enrolling 72 patients with acute rheumatoid arthritis (AR) of the lung and spleen qi deficiency type. Four patients dropped out, resulting in 68 participants who completed treatment. These participants were divided into an experimental group (n=34) and a control group (n=34). The experimental group consisted of 16 males and 18 females, while the control group comprised 14 males and 20 females. In both groups, females outnumbered males. The mean age of patients in the experimental group was 28.06 ± 5.20 years, while that in the control group was 27.50 ± 5.90 years. The mean disease duration was 3 years in the experimental group and 2 years in the control group. There were no statistically significant differences between the two groups in terms of gender, age, disease duration, TNSS score, TNNSS score, RQLQ score, and serum total IgE, IgG4, IL-4, IL-5, and IL-33 levels (P > 0.05), indicating comparability. 5. Treatment plan:

[0040] The experimental group was treated with moxa sticks containing lung-tonifying and spleen-strengthening herbs. Moxibustion therapy The control group received moxibustion treatment with moxa sticks (without other medications). Treatment was administered once daily for 30-40 minutes, with one course of treatment lasting 7 days. Three consecutive courses of treatment were administered for statistical analysis of efficacy. The Moxibustion therapy The specific steps are: S1. Acupoints: Dazhui (GV14), Fengmen (BL12) (bilateral), Feishu (BL13) (bilateral), Pishu (BL20) (bilateral), Weishu (BL21) (bilateral); The acupoints were selected in accordance with the "Names and Locations of Acupoints" (GB / T12346-2021) standard formulated by the State Administration of Traditional Chinese Medicine in 2021. Dazhui (GV 14): On the posterior midline, in the depression below the spinous process of the seventh cervical vertebra; Fengmen (BL 12): On the back, below the spinous process of the second thoracic vertebra, 1.5 cun lateral to the midline; Feishu (BL 13): On the back, below the spinous process of the third thoracic vertebra, 1.5 cun lateral to the midline; Spleen Shu (BL 20): On the back, below the spinous process of the eleventh thoracic vertebra, 1.5 cun lateral to the midline; Stomach Shu (BL 21): On the back, below the spinous process of the twelfth thoracic vertebra, 1.5 cun lateral to the midline; S2. Moxibustion: Instruct the subject to lie prone, fully exposing the skin on the back. After routine local disinfection, the doctor holds a Chinese herbal moxa stick, lights one end with an alcohol lamp, then places it into a moxibustion device (moxibustion box) and fixes it in place. Place the moxibustion box at the corresponding acupoint, and adjust the moxa stick to keep it 2-3cm away from the skin. The treatment should be performed until the patient feels warmth without burning. Each treatment lasts for 30-40 minutes. The treatment should continue until the skin becomes flushed. Ideally, the patient should feel the sensation of "qi" during moxibustion, which may include muscle twitching, a feeling of comfort, distension, heaviness, itching, or a transmission or penetration of the moxibustion sensation. 6. Clinical efficacy observation:

[0041] 6.1 Observation indicators: 6.1.1 Key Outcome Indicators: Total Nasal Symptom Subscale (TNSS): The scale is based on the four main clinical symptoms of AR: nasal congestion, nasal itching, sneezing, and runny nose. Each symptom is divided into five levels according to its severity, from mild to severe: no symptoms, mild symptoms, moderate symptoms, severe symptoms, and very severe symptoms, with corresponding scores of 0, 1, 2, 3, and 4.

[0042] 6.1.2 Secondary outcome indicators: (1) Total Subscale of Rhinitis Accompanying Symptoms (TNNSS): This scale scores the presence or absence of symptoms such as runny nose, tearing, itchy nose or eyes, pain in the nose or upper jaw, and headache: 0 points for no symptoms and 1 point for symptoms. (2) Quality of Life Scale (RQLQ) for Nasal Conjunctivitis: This scale surveys patients' activities, sleep, non-nasal and ocular symptoms, daily life problems, nasal symptoms, ocular symptoms, and emotions related to acute rhinitis (AR) across 7 dimensions and 26 items, thereby comprehensively assessing the extent to which patients' quality of life is affected. Scores for each question increase progressively according to the degree of distress experienced; higher scores indicate lower quality of life. (3) Traditional Chinese Medicine Syndrome Scoring Scale: This scale is based on the diagnostic criteria for rhinitis (lung and spleen qi deficiency type) in "Integrated Traditional Chinese and Western Medicine Otorhinolaryngology" (3rd edition). Each symptom score is assigned from mild to severe as follows: no symptoms = 0 points, mild symptoms = 1 point, moderate symptoms = 2 points, and severe symptoms = 3 points. A higher score indicates more severe lung and spleen qi deficiency symptoms. (4) Serum IgE, IL-5, and IL-33 levels: Two groups of patients were each given 3 mL of fasting venous blood in the morning before and after treatment. The blood was centrifuged (3000 r·min-1, centrifugation for 10 min) and the serum was collected. The serum was stored at -80℃. After all samples were collected, the serum IgE, IL-4 and IL-5 were detected by ELISA. (5) Follow-up efficacy evaluation criteria table: This form is used for follow-up within 1 month and 3 months after the end of treatment to record the patient's rhinitis recurrence.

[0043] 6.2 Data Recording Method: The total subscale of nasal symptoms (TNSS), the total subscale of rhinitis-associated symptoms (TNNSS), the quality of life scale (RQLQ) for nasal conjunctivitis, the TCM syndrome scoring scale, and serum IgE, IL-4, and IL-5 levels were recorded and statistically analyzed for both groups of patients before and after treatment. The follow-up efficacy evaluation criteria were also recorded. The original data records were required to be accurate, timely, complete, and properly preserved.

[0044] 6.3 Evaluation Time: First evaluation: Before the start of treatment, the patient's main symptoms and signs were evaluated once using a scale and serum was collected; Second evaluation: At the end of the treatment course, the patient's main symptoms and signs were evaluated once using a scale and serum was collected; The third evaluation: follow-up, which takes place within 3 months after the end of the treatment course, uses a scale to evaluate the patient's main symptoms and signs once, and assesses the recurrence rate.

[0045] 6.4. Efficacy Evaluation Criteria: According to the efficacy criteria established in the "Principles and Recommendations for the Diagnosis and Treatment of Allergic Rhinitis", the efficacy was evaluated using the Total Nasal Symptom Scale (TNSS) as the primary outcome indicator and the nimodipine grading method after treatment. Therapeutic effect index = (TNSS score before treatment - TNSS score after treatment) / TNSS score before treatment × 100%; Significant improvement: Major and minor symptoms are significantly improved, with an efficacy index ≥66%; Effective: Major and minor symptoms show significant improvement; efficacy rate < 25% < efficacy index < 66%; Ineffective: No significant improvement in primary or secondary symptoms (including maintaining the status quo), or even worsening of symptoms; efficacy index ≤25%; Overall effectiveness rate = [(number of cases with significant effects + number of cases with effective results) / total number of cases] × 100% 6.5 Recurrence rate: Patients with an efficacy index >25% (i.e., patients who responded to treatment) in both groups were followed up 3 months after the end of treatment. The recurrence rate and symptom score were used as the main assessment indicators to measure the treatment effect. Relapse: The increase in the patient's total symptom score at follow-up is ≥30% of the total symptom score after the last treatment. No recurrence: The increase in the patient's total symptom score at follow-up was less than 30% of the total symptom score at the end of the last treatment; The recurrence rate is assessed using the following formula: Relapse rate = [Number of relapse cases / (Number of cases with significant effect + Number of cases with effective results)] × 100%.

[0046] 6.6 Safety Evaluation: If patients experience adverse reactions during the trial, they should immediately inform their doctor. The doctor will observe and record any adverse events such as allergies or infections, and take appropriate measures promptly. Adverse reactions are assessed in four levels according to their severity, referring to the "Guiding Principles for Clinical Research of New Traditional Chinese Medicines 2002 (Trial Implementation)". Level 1: Safe, no adverse reactions; Level 2: Relatively safe. If adverse reactions occur, no treatment is required and treatment can continue. Level 3: There are safety concerns and moderate adverse reactions; treatment can continue after intervention. Level 4: The trial was terminated due to adverse reactions. 7. Statistical analysis:

[0047] SPSS 26.0 statistical software was used for analysis. If the measurement data conformed to a normal distribution, the mean plus or minus the standard deviation was used. Mean ± s is used. Within-group comparisons are performed using paired-samples t-tests, and between-group comparisons using independent-samples t-tests. If the data does not conform to a normal distribution, the median [M(P25, P75)] is used. Within-group comparisons are performed using the Wilcoxon rank-sum test, and between-group comparisons using the Mann-Whitney U rank-sum test. Count data are expressed as frequency and percentage n (%). Unordered categorical data are analyzed using the χ² test, and ordered categorical data are analyzed using the Mann-Whitney U rank-sum test. P < 0.05 indicates statistical significance; and all statistical data are analyzed at the significance level. α =0.05 analysis.

[0048] This study recruited a total of 72 patients with lung-spleen qi deficiency type allergic rhinitis who met the inclusion criteria from outpatient or inpatient care. Two patients dropped out of the experimental group (both due to personal reasons for failing to complete the treatment cycle and follow-up visits in time and voluntarily withdrawing), and two patients were in the control group (one was removed due to poor compliance during the study, and the other was removed because they received other treatments during the study, which affected the efficacy of the study). The actual number of cases completed was 68, including 34 in the experimental group and 34 in the control group. 7.1 General Data Analysis:

[0049] The demographic data of the two groups of subjects are shown in Table 1. Gender was an unordered categorical variable, and the chi-square test was used. Age and disease duration were continuous data; age followed a normal distribution, and the independent samples t-test was used; while disease duration did not follow a normal distribution, and the Mann-Whitney U rank-sum test was used. Statistical analysis showed no statistically significant differences in demographic data between the two groups. P (>0.05), therefore, the two groups of patients have similar basic characteristics and are comparable.

[0050] Table 1. Baseline comparison of demographic data between the two groups of patients.

[0051] Note: a) Chi-square test was used, and the statistical value was χ²; b) Two independent samples t-test was used, and the statistical value was t; c) Nonparametric rank-sum test was used, and the statistical value was... Z 7.2 Comparison of various indicators between the two groups of patients before treatment: 7.2.1 Comparison of TNSS levels between the two groups of patients before treatment:

[0052] Table 2 shows the comparison of TNSS scores and total scores between the two groups before treatment. The data for nasal congestion, nasal itching, runny nose, sneezing, and total TNSS scores did not conform to a normal distribution, and the Mann-Whitney U rank-sum test was used. Statistical analysis showed that the differences in TNSS scores and total scores between the two groups before treatment did not reach a statistically significant level. P(>0.05), making them comparable.

[0053] Table 2 Comparison of TNSS symptom scores between the two groups before treatment (M(P25, P75))

[0054] Note: Compared with the pre-treatment level in this group, * P <0.05. 7.2.2 Comparison of TCM lung and spleen qi deficiency symptom scores between the two groups of patients before treatment:

[0055] Table 3 shows a comparison of the TCM lung and spleen qi deficiency symptom scores between the two groups before treatment. The scores for spontaneous sweating, aversion to wind and cold, fatigue, decreased appetite, postprandial abdominal distension, and the total TCM symptom score did not conform to a normal distribution between the two groups, and the Mann-Whitney U rank-sum test was used. Statistical analysis showed that before treatment, the differences in the individual TCM lung and spleen qi deficiency symptom scores and the total score between the two groups did not reach a statistically significant level. P (>0.05), making them comparable.

[0056] Table 3 Comparison of TCM lung and spleen qi deficiency symptom scores before and after treatment in the two groups (M(P25, P75)).

[0057] Note: Compared with the pre-treatment level in this group, * P <0.05. 7.2.3 Comparison of subjective indicators between the two groups of patients before treatment:

[0058] Table 4 shows a comparison of subjective indicators between the two groups before treatment. Both groups' TNNSS and RQLQ scores before treatment followed a normal distribution, and a two-sample t-test was used. Statistical analysis showed no significant differences in TNNSS and RQLQ scores. P (>0.05), making them comparable.

[0059] Table 4 Comparison of subjective indicators between the two groups of patients before treatment ( ±s)

[0060] Note: Compared with the pre-treatment level in this group, * P <0.05. 7.2.4 Comparison of objective indicators between the two groups of patients before treatment:

[0061] Table 5 shows a comparison of objective indicators between the two groups before treatment. Before treatment, serum total IL-33 and IL-5 in both groups followed a normal distribution, which was analyzed using a two-sample t-test; however, IgE, IL-4, and IgG-4 did not follow a normal distribution, which was analyzed using a Mann-Whitney U rank-sum test. Statistical analysis showed no significant differences in objective indicators between the two groups before treatment. P (>0.05), making them comparable.

[0062] Table 5 Comparison of objective indicators between the two groups of patients before treatment

[0063] Note: b uses a two-independent-samples t-test, and the statistic is t; c uses a nonparametric rank-sum test, and the statistic is t. Z . 7.3 Statistical analysis of various indicators after treatment in the two groups of patients: 7.3.1 Comparison of TNSS scores before and after treatment in the two groups of patients:

[0064] Wilcoxon rank-sum test was used to compare the differences in TNSS scores and total scores before and after treatment in both groups. Statistical analysis showed that after treatment, the scores for nasal congestion, nasal itching, runny nose, sneezing, and total TNSS were significantly lower in both groups than before treatment, and the differences were statistically significant. P <0.05), indicating that both the treatment group and the control group can improve nasal symptoms in AR patients.

[0065] After treatment, the Mann-Whitney U rank-sum test was used to compare the TNSS scores and total score between the two groups. After treatment, the symptom scores of nasal itching, runny nose, and sneezing, as well as the total nasal symptom score, were significantly reduced in both groups. P <0.05 indicates a statistically significant difference, suggesting that the experimental group showed a significant advantage over the control group in relieving symptoms of nasal itching, runny nose, and sneezing. However, there was no statistically significant difference in the score for improving nasal congestion symptoms. P >0.05), indicating that the two groups had comparable efficacy in improving nasal congestion symptoms. Specific results are shown in Table 6.

[0066] Table 6. Comparison of TNSS levels before and after treatment in the two groups (P25, P75)

[0067] Note: Compared with the pre-treatment level in this group, * P <0.05. 7.3.2 Comparison of TCM lung and spleen qi deficiency symptom scores before and after treatment in the two groups of patients:

[0068] Wilcoxon rank-sum test was used to compare the differences in the scores and total scores of various TCM symptoms of lung and spleen qi deficiency before and after treatment in both groups. Statistical analysis showed that after treatment, the scores for spontaneous sweating, aversion to wind and cold, fatigue, decreased appetite, postprandial abdominal distension, and the total TCM symptoms in both groups were significantly lower than before treatment, and the differences were statistically significant. P <0.05), indicating that both the treatment group and the control group could improve the symptoms of lung and spleen qi deficiency in patients.

[0069] The Mann-Whitney U rank-sum test was used to compare the TNSS scores and total scores between the two groups after treatment. After treatment, the scores for spontaneous sweating, aversion to wind and cold, fatigue, loss of appetite, postprandial abdominal distension, and total TCM symptoms were significantly reduced in both groups. P The difference was <0.05, indicating a statistically significant difference, suggesting that the experimental group was more effective than the control group in improving the symptoms of lung and spleen qi deficiency. Specific results are shown in Table 7.

[0070] Table 7 Comparison of TCM lung and spleen qi deficiency symptom scores before and after treatment in the two groups (M (P25, P75)).

[0071] Note: Compared with the pre-treatment level in this group, * P <0.05. 7.3.3 Comparison of TNNSS before and after treatment in the two groups of patients:

[0072] The Wilcoxon rank-sum test was used to compare the differences in TNNSS scores before and after treatment in both groups. Statistical analysis showed that the TNNSS scores of patients in both groups were significantly lower after treatment than before treatment, and the differences were statistically significant. P <0.05), and the difference in TNNSS scores between the experimental group and the control group was significantly greater.

[0073] The Mann-Whitney U rank-sum test was used to compare the TNNSS scores between the two groups after treatment, and the differences were statistically significant. P <0.05). See Table 8 for specific results.

[0074] Table 8 Comparison of TNNSS levels before and after treatment in the two groups (P25, P75)

[0075] Note: Compared with the pre-treatment level in this group, * P <0.05. 7.3.4 Comparison of RQLQ before and after treatment in the two groups of patients:

[0076] The Wilcoxon rank-sum test was used to compare the differences in RQLQ scores before and after treatment in both groups. Statistical analysis showed that after treatment, the RQLQ scores of both groups were significantly lower than before treatment, and the difference was statistically significant. P <0.05).

[0077] The Mann-Whitney U rank-sum test was used to compare the RQLQ scores between the two groups after treatment, and the differences were statistically significant. P <0.05). See Table 9 for specific results.

[0078] Table 9 Comparison of RQLQ before and after treatment in the two groups (P25, P75) 7.3.5 Comparison of serum total IgE before and after treatment in the two groups of patients:

[0079] The Wilcoxon rank-sum test was used to compare the differences in serum total IgE before and after treatment in both groups. Statistical analysis showed that serum total IgE levels were significantly lower in both groups after treatment than before treatment, and the differences were statistically significant. P <0.05).

[0080] The Mann-Whitney U rank-sum test was used to compare serum total IgE levels between the two groups after treatment. After treatment, serum total IgE levels decreased significantly in both groups. P <0.05 indicates that the difference is statistically significant. See Table 10 for specific results.

[0081] Table 10 IgE comparison with M (P25, P75) 7.3.6 Comparison of serum total IL-33 before and after treatment in the two groups of patients:

[0082] The Wilcoxon rank-sum test was used to compare the differences in serum total IL-33 before and after treatment in both groups. Statistical analysis showed that serum total IL-33 was significantly lower in both groups after treatment than before treatment, and the difference was statistically significant. P <0.05).

[0083] The Mann-Whitney U rank-sum test was used to compare serum total IL-33 levels between the two groups after treatment. After treatment, serum total IL-33 levels were significantly reduced in both groups. P <0.05 indicates that the difference is statistically significant. See Table 11 for specific results.

[0084] Table 11 IL-33 vs. M (P25, P75) 7.3.7 Comparison of serum total IL-4 before and after treatment in the two groups of patients:

[0085] The Wilcoxon rank-sum test was used to compare the differences in serum total IL-4 before and after treatment in both groups. Statistical analysis showed that serum total IL-4 levels were significantly lower in both groups after treatment than before treatment, and the differences were statistically significant. P <0.05).

[0086] The Mann-Whitney U rank-sum test was used to compare serum total IL-4 levels between the two groups after treatment. After treatment, serum total IL-4 levels were significantly reduced in both groups. P <0.05 indicates that the difference is statistically significant. See Table 12 for specific results.

[0087] Table 12 IL-4 vs. M (P25, P75) 7.3.8 Comparison of serum total IL-5 before and after treatment in the two groups of patients:

[0088] The Wilcoxon rank-sum test was used to compare the differences in serum total IL-5 before and after treatment in both groups. Statistical analysis showed that serum total IL-5 levels were significantly lower in both groups after treatment than before treatment, and the differences were statistically significant. P <0.05).

[0089] The Mann-Whitney U rank-sum test was used to compare serum total IL-5 levels between the two groups after treatment. After treatment, serum total IL-5 levels were significantly reduced in both groups. P <0.05 indicates that the difference is statistically significant. See Table 13 for specific results.

[0090] Table 13 IL-5 vs. M (P25, P75) 7.3.9 Comparison of serum total IgG-4 levels before and after treatment in the two groups of patients:

[0091] The differences in serum total IgG-4 levels before and after treatment in both groups followed a normal distribution, as analyzed by a two-sample t-test. Statistical analysis showed that after treatment, serum total IgG-4 levels in both groups were significantly lower than before treatment, with statistically significant differences. P <0.05).

[0092] The serum total IgG-4 levels were compared between the two groups after treatment using an independent samples t-test, and the difference was not statistically significant. P>0.05), indicating that the two groups were equally effective in increasing serum total IgG-4 levels. Specific results are shown in Table 14.

[0093] Table 14. IgG-4 vs. M (P25, P75) 7.3.10. Efficacy Analysis:

[0094] After treatment, the total effective rate in the experimental group was 97.1%, while the total effective rate in the control group was 82.4%. The results were analyzed using the chi-square test. P =0.046 < 0.05, the difference is statistically significant, indicating that the total effective rate of the experimental group is higher than that of the control group. See Table 15 for specific results.

[0095] Table 15 Comparison of therapeutic effects between the two groups of patients 7.3.11 Comparison of recurrence rates:

[0096] The recurrence rate of the two groups of patients within three months after the end of treatment was observed. Ineffective cases were excluded. A total of 33 cases showed improvement in the experimental group, and 28 cases showed improvement in the control group. The recurrence rate in the experimental group was 9.1%, and the recurrence rate in the control group was 28.6%. The results were analyzed using the chi-square test. P =0.049 < 0.05, the difference was statistically significant, indicating that the experimental group was superior to the control group in reducing the recurrence rate of patients. Specific results are shown in Table 16.

[0097] Table 16 Comparison of recurrence rates between the two groups of patients (n%) 8. Security Assessment:

[0098] During this study, no adverse events such as local burns, coughing, sneezing, or dizziness occurred in any participant in the experimental group. One subject in the control group experienced fatigue and a mild, transient headache after moxibustion, which subsided spontaneously after rest. The treatment time was subsequently adjusted, and the patient was advised to maintain a good condition before treatment; this subject did not experience the same discomfort again. No other side effects such as shortness of breath, chest tightness, respiratory distress, or syncope occurred in either group, indicating a high level of safety.

[0099] While conducting experiments on Example 1, the same experiments were also conducted on other examples, and the same or similar results were obtained. These will not be described in detail here. 9. Conclusion:

[0100] This invention relates to a lung-tonifying and spleen-strengthening moxa stick specifically formulated to treat allergic rhinitis caused by lung and spleen qi deficiency. The formula is based on the principles of principal, assistant, adjuvant, and guide herbs, making it scientifically sound. The preparation method is simple, easy to operate, and convenient to use. It allows the medicine and the heat of the moxa to work synergistically, reaching the meridians directly through acupoint moxibustion. This warms the meridians, dispels cold, and regulates the internal organs, simultaneously achieving multiple effects such as tonifying lung qi, invigorating spleen yang, and resolving dampness and stagnation. By enhancing lung and spleen function, it fundamentally strengthens the body's disease resistance and repair capabilities, reversing chronic deficiency and effectively improving rhinitis-related symptoms. This treatment improves symptoms and quality of life by reducing serum concentrations of inflammatory cytokines IgE, IL-4, IL-5, and IL-33 in patients with lung and spleen qi deficiency type allergic rhinitis, increasing IgG4 levels, regulating inflammatory responses, and inhibiting allergic reactions. Compared with ordinary moxibustion, medicated moxibustion can prolong the duration of therapeutic effects, reduce the frequency of recurrences, and improve symptoms such as pale complexion, fatigue, shortness of breath, weakness in the limbs, poor appetite, and loose stools caused by lung and spleen qi deficiency. The efficacy rate for treating lung and spleen qi deficiency type allergic rhinitis is as high as 97%, and the medication is safe with a low recurrence rate, making it of practical clinical and promotional value.

Claims

1. A traditional Chinese medicine moxa stick for treating allergic rhinitis of lung and spleen qi deficiency type by tonifying lung and regulating spleen, characterized in that, It is made from Chinese medicinal herbs and moxa wool by weight. The Chinese medicinal herbs are: 9-11g of raw Astragalus membranaceus, 5.5-6.5g of Atractylodes macrocephala, 2.5-3.5g of Codonopsis pilosula, 2.5-3.5g of Angelica dahurica, 2.5-3.5g of Saposhnikovia divaricata, 2.5-3.5g of Citrus reticulata peel, 2.5-3.5g of Magnolia biondii, 2.5-3.5g of Mentha haplocalyx, and 1.8-2.2g of dried ginger. Grind them into a fine powder, dry them, and add 2.5 times the weight of moxa wool to the fine powder and mix them evenly. Roll mulberry bark paper into a cylindrical paper tube with a length of 20cm, a diameter of 1.6-4.0cm, and 5-7 layers. Spread egg white evenly on the surface of the paper tube, wrap it with another layer of mulberry bark paper, dry it, and then fill the paper tube with the medicine and tamp it down. This is the finished Chinese medicinal moxa stick.

2. The lung and spleen tonifying and transporting type traditional Chinese medicine moxa stick for treating allergic rhinitis of lung and spleen qi deficiency according to claim 1, characterized in that, It is made from Chinese medicinal herbs and moxa wool by weight. The Chinese medicinal herbs are 10g of raw astragalus, 6g of atractylodes macrocephala, 3g of codonopsis pilosula, 3g of angelica dahurica, 3g of saposhnikovia divaricata, 3g of tangerine peel, 3g of magnolia flower, 3g of mint, and 2g of dried ginger. They are ground into a fine powder, dried, and then mixed with 90g of moxa wool to form the medicine. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 1.6cm, and 5 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. Then the medicine is filled into the paper tube and compacted to form the finished Chinese medicinal moxa stick.

3. The moxa stick for treating allergic rhinitis of the lung and spleen deficiency type according to claim 1, characterized in that, It is made from Chinese medicinal herbs and moxa wool by weight. The Chinese medicinal herbs are 9g of raw astragalus, 5.5g of atractylodes macrocephala, 2.5g of codonopsis pilosula, 2.5g of angelica dahurica, 2.5g of saposhnikovia divaricata, 2.5g of tangerine peel, 2.5g of magnolia flower, 2.5g of mint, and 1.8g of dried ginger. They are ground into a fine powder, dried, and then mixed with 75.75g of moxa wool. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 1.8cm, and 5 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. The paper tube is then filled with the medicine and compacted to make the finished Chinese medicinal moxa stick.

4. The moxa stick for treating allergic rhinitis of the lung and spleen deficiency type according to claim 1, characterized in that, It is made from Chinese medicinal herbs and moxa wool by weight. The Chinese medicinal herbs are 11g of raw astragalus, 6.5g of atractylodes macrocephala, 3.5g of codonopsis pilosula, 3.5g of angelica dahurica, 3.5g of saposhnikovia divaricata, 3.5g of tangerine peel, 3.5g of magnolia flower, 3.5g of mint, and 2.2g of dried ginger, which are ground into a fine powder, dried, and then mixed with 101.75g ​​of moxa wool. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 2.6cm, and 6 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. Then the paper tube is filled with the medicine and compacted to make the finished Chinese medicinal moxa stick.

5. The moxa stick for treating allergic rhinitis of the lung and spleen deficiency type according to claim 1, characterized in that, It is made from Chinese medicinal herbs and moxa wool by weight. The Chinese medicinal herbs are 9g of raw astragalus, 6.5g of atractylodes macrocephala, 2.5g of codonopsis pilosula, 3.5g of angelica dahurica, 2.5g of saposhnikovia divaricata, 3.5g of tangerine peel, 2.5g of magnolia flower, 3.5g of mint, and 1.8g of dried ginger. They are ground into a fine powder, dried, and then mixed with 88.25g of moxa wool. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 2.8cm, and 6 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. The paper tube is then filled with the medicinal herbs and compacted to form the finished Chinese medicinal moxa stick.

6. The moxa stick for treating allergic rhinitis of the lung and spleen deficiency type according to claim 1, characterized in that, It is made from Chinese medicinal herbs and moxa wool by weight. The Chinese medicinal herbs are 11g of raw astragalus, 5.5g of atractylodes macrocephala, 3.5g of codonopsis pilosula, 2.5g of angelica dahurica, 3.5g of saposhnikovia divaricata, 2.5g of tangerine peel, 3.5g of magnolia flower, 2.5g of mint, and 2.2g of dried ginger, which are ground into a fine powder, dried, and mixed with 91.75g ​​of moxa wool. Mulberry bark paper is rolled into a cylindrical tube with a length of 20cm, a diameter of 4cm, and 7 layers. Egg white is evenly coated on the surface of the paper tube, and then another layer of mulberry bark paper is wrapped around it and dried. Then the paper tube is filled with the medicine and compacted to make the finished Chinese medicinal moxa stick.

Images